Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence
- PMID: 40215972
- PMCID: PMC12097926
- DOI: 10.1016/j.cels.2025.101260
Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence
Abstract
The anti-tumor function of engineered T cells expressing chimeric antigen receptors (CARs) is dependent on signals transduced through intracellular signaling domains (ICDs). Different ICDs are known to drive distinct phenotypes, but systematic investigations into how ICD architectures direct T cell function-particularly at the molecular level-are lacking. Here, we use single-cell sequencing to map diverse signaling inputs to transcriptional outputs, focusing on a defined library of clinically relevant ICD architectures. Informed by these observations, we functionally characterize transcriptionally distinct ICD variants across various contexts to build comprehensive maps from ICD composition to phenotypic output. We identify a unique tonic signaling signature associated with a subset of ICD architectures that drives durable in vivo persistence and efficacy in liquid, but not solid, tumors. Our findings work toward decoding CAR signaling design principles, with implications for the rational design of next-generation ICD architectures optimized for in vivo function.
Keywords: CAR T cells; T cell signaling; T cells; chimeric antigen receptors; immunotherapy; intracellular signaling domains; persistence; pooled screens; single-cell RNA sequencing; tonic signaling.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.E.B. is a founder, consultant, and equity holder of Kelonia Therapeutics and Abata Therapeutics. M.V.M. is an inventor on patents related to adoptive cell therapies, held by the Massachusetts General Hospital (some licensed to Promab and Luminary) and the University of Pennsylvania (some licensed to Novartis). M.V.M. receives grant/research support from Kite Pharma and Moderna; serves as a consultant for multiple companies involved in cell therapies; holds equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, Century Therapeutics, Neximmune, Oncternal, and TCR2; and serves on the Board of Directors of 2Seventy Bio. C.R.P. is currently employed at TwoStep Therapeutics. K.S.G. is currently employed at Ginkgo Bioworks, Inc.
Update of
-
Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence.bioRxiv [Preprint]. 2024 May 2:2024.04.29.591541. doi: 10.1101/2024.04.29.591541. bioRxiv. 2024. Update in: Cell Syst. 2025 May 21;16(5):101260. doi: 10.1016/j.cels.2025.101260. PMID: 38746119 Free PMC article. Updated. Preprint.
References
-
- Majzner RG, and Mackall CL (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med 25, 1341–1355. - PubMed